Invitae Corporation – NYSE:NVTA
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Invitae stock price monthly change
-92.60%
month
Invitae stock price quarterly change
-92.13%
quarter
Invitae stock price yearly change
-98.22%
year
Invitae key metrics
Market Cap | 5.44M |
Enterprise value | 1.84B |
P/E | -0.11 |
EV/Sales | 3.56 |
EV/EBITDA | -0.62 |
Price/Sales | 0.67 |
Price/Book | 3.42 |
PEG ratio | N/A |
EPS | -5.38 |
Revenue | 481.58M |
EBITDA | -331.86M |
Income | -1.44B |
Revenue Q/Q | -9.20% |
Revenue Y/Y | -7.38% |
Profit margin | -601.64% |
Oper. margin | -138.34% |
Gross margin | 19.18% |
EBIT margin | -138.34% |
EBITDA margin | -68.91% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInvitae stock price history
Invitae stock forecast
Invitae financial statements
| Dec 2022 | 122.45M | -99.81M | -81.51% |
|---|---|---|---|
| Mar 2023 | 117.35M | -192.18M | -163.76% |
| Jun 2023 | 120.53M | -206.51M | -171.33% |
| Sep 2023 | 121.24M | -942.10M | -777.05% |
| 2025 | 592.46M | -413.38M | -69.77% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 1954116000 | 1.85B | 94.79% |
|---|---|---|---|
| Mar 2023 | 1691663000 | 1.72B | 102.17% |
| Jun 2023 | 1523039000 | 1.72B | 113.18% |
| Sep 2023 | 535115000 | 1.61B | 302.46% |
| Dec 2022 | -82.02M | 121.89M | 599K |
|---|---|---|---|
| Mar 2023 | -34.39M | 73.87M | -135.76M |
| Jun 2023 | -54.90M | 116.06M | 876K |
| Sep 2023 | -66.89M | 5.11M | -3.38M |
Invitae alternative data
| Aug 2023 | 1,700 |
|---|---|
| Sep 2023 | 1,700 |
| Oct 2023 | 1,700 |
| Nov 2023 | 1,700 |
| Dec 2023 | 1,700 |
| Jan 2024 | 1,700 |
| Feb 2024 | 1,700 |
| Mar 2024 | 1,700 |
| Apr 2024 | 1,700 |
| May 2024 | 1,700 |
| Jun 2024 | 1,700 |
| Jul 2024 | 1,700 |
Invitae other data
93.57%
-1.70%
of NVTA is owned by hedge funds
287
-25
197.37M
-10.66M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2022 | 0 | 40783 |
| Dec 2022 | 0 | 55979 |
| Mar 2023 | 0 | 9728 |
| May 2023 | 0 | 206847 |
| Jun 2023 | 0 | 14165 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | NUSSBAUM ROBERT L officer: Chief Me.. | Common Stock | 7,086 | $1.38 | $9,757 | ||
Sale | BRIDA THOMAS officer: See Remarks | Common Stock | 7,079 | $1.38 | $9,748 | ||
Sale | KNIGHT KENNETH D. director, officer.. | Common Stock | 45,432 | $1.2 | $54,473 | ||
Sale | KNIGHT KENNETH D. director, officer.. | Common Stock | 45,432 | $1.2 | $54,473 | ||
Sale | NUSSBAUM ROBERT L officer: Chief Me.. | Common Stock | 26,476 | $1.2 | $31,745 | ||
Sale | WEN YAFEI officer: Chief Financial Officer | Common Stock | 86,904 | $1.6 | $138,699 | ||
Sale | WERNER ROBERT F. officer: Chief Ac.. | Common Stock | 21,559 | $1.2 | $25,849 | ||
Sale | BRIDA THOMAS officer: See Remarks | Common Stock | 26,476 | $1.2 | $31,745 | ||
Sale | WEN YAFEI | Common Stock | 2,625 | $1.41 | $3,701 | ||
Sale | NUSSBAUM ROBERT L | Common Stock | 2,625 | $1.41 | $3,701 |
| Patent |
|---|
Grant Utility: Sequence assembly Filling date: 13 Feb 2020 Issue date: 19 Jul 2022 |
Application SYSTEM AND METHOD FOR CHARACTERIZING BIOLOGICAL SEQUENCE DATA THROUGH A PROBABILISTIC DATA STRUCTURE Filling date: 9 Jun 2021 Issue date: 24 Mar 2022 |
Application Filling date: 17 May 2021 Issue date: 2 Sep 2021 |
Application Filling date: 29 Mar 2021 Issue date: 29 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 9 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 28 Feb 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Sean Emerson George Ph.D. (1974) Co-Founder, Pres, Chief Executive Officer & Director | $451,350 |
| Mr. Kenneth D. Knight (1961) Chief Operating Officer | $428,500 |
Mr. Lee Bendekgey (1958) Chief Policy Officer | $383,640 |
Invitae's Battle To Reignite Revenue Growth And Overcome Financial Challenges
Exact Sciences' Shift In Strategy: Targeting Positive Adjusted EBITDA
Invitae Investors Face More Dilution
23andMe Looking Promising For The Long Term
Exact Sciences Up 25% YTD: Here Is What To Expect In 2023
Sema4: Restructuring Plan Figures Don't Add Up
Natera's Worrisome Cash Burn
Invitae: This Turnaround Could Be Painful
Veracyte: Sustainable Rally Supported By Spectacular Execution In Q3
-
When is Invitae's next earnings date?
Unfortunately, Invitae's (NVTA) next earnings date is currently unknown.
-
Does Invitae pay dividends?
No, Invitae does not pay dividends.
-
How much money does Invitae make?
Invitae has a market capitalization of 5.44M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.13% to 516.3M US dollars.
-
What is Invitae's stock symbol?
Invitae Corporation is traded on the NYSE under the ticker symbol "NVTA".
-
What is Invitae's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Invitae?
Shares of Invitae can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Invitae's key executives?
Invitae's management team includes the following people:
- Dr. Sean Emerson George Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 51, pay: $451,350)
- Mr. Kenneth D. Knight Chief Operating Officer(age: 64, pay: $428,500)
- Mr. Lee Bendekgey Chief Policy Officer(age: 67, pay: $383,640)
-
Is Invitae founder-led company?
Yes, Invitae is a company led by its founder Dr. Sean Emerson George Ph.D..
-
How many employees does Invitae have?
As Jul 2024, Invitae employs 1,700 workers.
-
When Invitae went public?
Invitae Corporation is publicly traded company for more then 10 years since IPO on 12 Feb 2015.
-
What is Invitae's official website?
The official website for Invitae is invitae.com.
-
Where are Invitae's headquarters?
Invitae is headquartered at 1400 16th Street, San Francisco, CA.
-
How can i contact Invitae?
Invitae's mailing address is 1400 16th Street, San Francisco, CA and company can be reached via phone at +41 53747782.
Invitae company profile:
Invitae Corporation
invitae.comExchange:
NYSE
Full time employees:
1,700
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
1400 16th Street
San Francisco, CA 94103
San Francisco, CA 94103
CIK: 0001501134
ISIN: US46185L1035
CUSIP: 46185L103
